Dr. Marc Bonaca on the VOYAGER PAD Study

The VOYAGER PAD study demonstrated the treatment combination of rivaroxaban (XARELTO) was superior to aspirin alone among patients with lower extremity peripheral artery disease (PAD) undergoing revascularization. Lead study investigator Dr. Marc Bonaca spoke with DocWire News about the study design and findings, and the impact the analysis can have on the cardiovascular landscape.